About | Free Trial

Last Update

2015-08-11T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Michael Wade?

Dr. Michael Wade Ph.D.

Executive Vice President, Global Medical Affairs and Strategic Development

UNITED THERAPEUTICS Corp

Direct Phone: (919) ***-****       

Email: m***@***.com

UNITED THERAPEUTICS Corp

1040 Spring St

Silver Spring, Maryland 20910

United States

Company Description

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic and cardiovascular, and infectious diseases and cancer. The Company’s principal t... more

Find other employees at this company (629)

Background Information

Employment History

Clinical Research Scientist
Cato Research Ltd

Education

Ph.D.

Web References (4 Total References)


Research Triangle Park :: RTP In the News

www.rtp.org [cached]

"We are pleased that Remodulin meets the criteria for bioequivalence," said Michael Wade, vice president of development and medical affairs at United Therapeutics.


Today's News

www.prnewswire.com [cached]

United Therapeutics Announces Promotion of Dean Bunce to Vice President, Regulatory Affairs and Michael Wade to Vice President, Development and Medical Affairs

...
RESEARCH TRIANGLE PARK, N.C., Nov. 13 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the promotions of Dean Bunce to Vice President of Regulatory Affairs and Michael Wade, Ph.D. to Vice President of Development and Medical Affairs.
...
Dr. Wade joined United Therapeutics in 1997 and has nearly ten years of drug development experience; Dr. Wade has led project teams in all phases investigating multiple therapeutic areas.
...
Likewise, Dr. Wade has been one of the key individuals responsible for the clinical development of Remodulin since its infancy, and is currently responsible for all post- approval studies of Remodulin, including the Phase IV Flolan transition study and the critical limb ischemia development effort."
...
Dr. Wade will continue to be responsible for all post-marketing studies of Remodulin(R) (treprostinil sodium) Injection, United Therapeutics' therapy for the treatment of pulmonary arterial hypertension, and for progressing early stage compounds into and through clinical development.United Therapeutics is a biotechnology company focused on combating cardiovascular, infectious and oncological diseases with unique therapeutic products.
Click here


Drugmax.com * The Premier Business-To-Business E-Commerce Trade Exchange for Professionals in the Pharmaceutical, Over-The-Counter, Health & Beauty and Private Label Industries/NewsAlert - Story

www.drugmax.newsalert.com [cached]

Our trial was designed to confirm the very positive results of BERCI2, said Michael Wade, Ph.D., Associate Director of Research and Development for United Therapeutics.Successful completion of this study will be an important milestone in our goal of filling a large unmet medical need for safe, effective treatments for intermittent claudication, which affects millions of people..

Beraprost is the first and only orally available analog of prostacyclin, a potent naturally occurring vasodilator and inhibitor of platelet aggregation.Beraprost was exclusively licensed to United Therapeutics by Toray Industries, Inc. of Japan for the North American market.In Japan, beraprost has been proven in clinical studies to be safe and effective for the treatment of peripheral vascular disease.The drug has been approved in Japan since 1994 and Toray's annual sales of beraprost there exceed $ 250 million.


DisabilityTimes.com: United Therapeutics Corporation Completes Enrollment In Phase III Intermittent Claudication Study

www.disabilitytimes.com [cached]

``Our trial was designed to confirm the very positive results of BERCI2 , '' said Michael Wade , Ph.D. , Associate Director of Research and Development for United Therapeutics. ``Successful completion of this study will be an important milestone in our goal of filling a large unmet medical need for safe , effective treatments for intermittent claudication , which affects millions of people.''.

Beraprost is the first and only orally available analog of prostacyclin , a potent naturally occurring vasodilator and inhibitor of platelet aggregation.Beraprost was exclusively licensed to United Therapeutics by Toray Industries , Inc. of Japan for the North American market.In Japan , beraprost has been proven in clinical studies to be safe and effective for the treatment of peripheral vascular disease.The drug has been approved in Japan since 1994 and Toray's annual sales of beraprost there exceed $250 million.
A Japanese study presented at the 1998 American Heart Association meeting suggests that beraprost may also improve survival in patients with pulmonary hypertension.

Similar Profiles

Other People with this Name

Other people with the name Wade

Tim Wade
Maine Association of Site Evaluators

Jodi Wade
Park

Bob Wade
Achievement Committee

Scotty Wade
Moose International Inc

Matthew Wade
Sport Medicine Massage

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory